Stefan H Hohnloser
Overview
Explore the profile of Stefan H Hohnloser including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
331
Citations
16755
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Lopes R, Granger C, Wojdyla D, McIntyre W, Alings M, Mani T, et al.
J Am Coll Cardiol
. 2024 Jul;
84(4):354-364.
PMID: 39019530
Background: ARTESiA (Apixaban for the Reduction of Thrombo-Embolism in Patients With Device-Detected Sub-Clinical Atrial Fibrillation) demonstrated that apixaban, compared with aspirin, significantly reduced stroke and systemic embolism (SE) but increased...
2.
Holst A, Tomcsanyi J, Vestbjerg B, Grunnet M, Sorensen U, Diness J, et al.
Nat Med
. 2023 Dec;
30(1):106-111.
PMID: 38092897
Existing antiarrhythmic drugs to treat atrial fibrillation (AF) have incomplete efficacy, contraindications and adverse effects, including proarrhythmia. AP30663, an inhibitor of the K2 channel, has demonstrated AF efficacy in animals;...
3.
Healey J, Lopes R, Granger C, Alings M, Rivard L, McIntyre W, et al.
N Engl J Med
. 2023 Nov;
390(2):107-117.
PMID: 37952132
Background: Subclinical atrial fibrillation is short-lasting and asymptomatic and can usually be detected only by long-term continuous monitoring with pacemakers or defibrillators. Subclinical atrial fibrillation is associated with an increased...
4.
Vinereanu D, Wojdyla D, Alexander J, Lopes R, Al-Khatib S, Gersh B, et al.
Am Heart J
. 2023 Jul;
265:132-136.
PMID: 37506747
Rate control is fundamental in the treatment of patients with atrial fibrillation (AF). The independent association of heart rate with outcomes and range of heart rate associated with best outcomes...
5.
Vamos M, Zsigmond E, Hohnloser S
Expert Opin Pharmacother
. 2023 Jun;
24(12):1403-1407.
PMID: 37306465
Introduction: Mexiletine is a class IB sodium-channel blocker. Unlike class IA or IC antiarrhythmic drugs, mexiletine rather shortens than prolongs action potential duration; therefore, it is less associated with proarrhythmic...
6.
Harrington J, Carnicelli A, Hua K, Wallentin L, Patel M, Hohnloser S, et al.
Circulation
. 2023 Apr;
147(23):1748-1757.
PMID: 37042255
Background: There is uncertainty surrounding the use of direct oral anticoagulants (DOACs) in patients with kidney dysfunction. Methods: Using the COMBINE AF (A Collaboration Between Multiple Institutions to Better Investigate...
7.
Benz A, Hohnloser S, Eikelboom J, Carnicelli A, Giugliano R, Granger C, et al.
Eur Heart J
. 2023 Apr;
44(20):1807-1814.
PMID: 37038327
Aims: The prognosis of patients with atrial fibrillation (AF) and ischemic stroke while taking oral anticoagulation is poorly understood. This study aimed to characterize the outcomes of patients following a...
8.
Blomstrom-Lundqvist C, Naccarelli G, McKindley D, Bigot G, Wieloch M, Hohnloser S
Europace
. 2023 Feb;
25(3):845-854.
PMID: 36758013
Aims: This post hoc analysis of the ATHENA trial (NCT00174785) assessed the effect of dronedarone on the estimated burden of atrial fibrillation (AF)/atrial flutter (AFL) progression to presumed permanent AF/AFL,...
9.
Kattih B, Operhalski F, Boeckling F, Hecker F, Michael F, Vamos M, et al.
Front Cardiovasc Med
. 2022 Nov;
9:1008311.
PMID: 36330004
Background: The subcutaneous implantable cardioverter-defibrillator (S-ICD) has been designed to overcome lead-related complications and device endocarditis. Lacking the ability for pacing or resynchronization therapy its usage is limited to selected...
10.
Buckley B, Lane D, Calvert P, Zhang J, Gent D, Daniel Mullins C, et al.
J Clin Med
. 2022 Jul;
11(13).
PMID: 35807073
Background: There is a plethora of real-world data on the safety and effectiveness of direct-acting oral anticoagulants (DOACs); however, study heterogeneity has contributed to inconsistent findings. We compared the effectiveness...